KRAS and neoplasm: All ADCs inhibited tumor growth in KRAS mutant EREG-high CRC cell line and patient-derived xenografts and were well tolerated, though the H231-EGC-qDuoDM gluc ADC showed increased tumor growth inhibition and survival.